Response to region of difference 1 (RD1) epitopes in human immunodeficiency virus (HIV)‐infected individuals enrolled with suspected active tuberculosis: a pilot study | Zendy

Vincenti D. | Zendy; Carrara S. | Zendy; Butera O. | Zendy; Bizzoni F. | Zendy; Casetti R. | Zendy; Girardi E. | Zendy; Goletti D. | Zendy

Open Access

Response to region of difference 1 (RD1) epitopes in human immunodeficiency virus (HIV)‐infected individuals enrolled with suspected active tuberculosis: a pilot study

Author(s) -

Vincenti D.,

Carrara S.,

Butera O.,

Bizzoni F.,

Casetti R.,

Girardi E.,

Goletti D.

Publication year - 2007

Publication title -

clinical & experimental immunology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.329

H-Index - 135

eISSN - 1365-2249

pISSN - 0009-9104

DOI - 10.1111/j.1365-2249.2007.03462.x

Subject(s) - tuberculosis , tuberculin , immunology , mycobacterium tuberculosis , medicine , quantiferon , immune system , elispot , antigen , latent tuberculosis , interferon gamma , tuberculosis diagnosis , virology , interferon gamma release assay , t cell , pathology

Summary Tuberculosis is the most frequent co‐infection in human immunodeficiency virus (HIV)‐infected individuals, and which still presents diagnostic difficulties. Recently we set up an assay based on interferon (IFN)‐γ response to region of difference 1 (RD1) peptides selected by computational analysis which is associated with active Mycobacterium tuberculosis replication. The objective of this study was to investigate the response to RD1 selected peptides in HIV‐1‐infected individuals in a clinical setting. The mechanisms of this immune response and comparison with other immune assays were also investigated. A total of 111 HIV‐infected individuals with symptoms and signs consistent with active tuberculosis were enrolled prospectively. Interferon (IFN)‐γ responses to RD1 selected peptides and recall antigens were evaluated by enzyme‐linked immunospot assay. Results were correlated with CD4 + T cell counts, individuals' characteristics, tuberculin skin test, QuantiFERON‐TB Gold and T‐SPOT.TB. Results from 21 (19%) individuals were indeterminate due to in vitro cell anergy. Among ‘non‐anergic’ individuals, sensitivity for active tuberculosis of the assay based on RD1 selected peptides was 67% (24 of 36), specificity was 94% (three of 54). The assay also resulted positive in cases of extra‐pulmonary and smear‐negative pulmonary active tuberculosis. The response was mediated by CD4 + effector/memory T cells and correlated with CD4 + T cell counts, but not with plasma HIV‐RNA load. Moreover, the RD1 selected peptides assay had the highest diagnostic odds ratio for active tuberculosis compared to tuberculin skin test (TST), QuantiFERON‐TB Gold and T‐SPOT.TB. RD1 selected peptides assay is associated with M. tuberculosis replication in HIV‐infected individuals, although T cell anergy remains an important obstacle to be overcome before the test can be proposed as a diagnostic tool.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research